Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Amneal Pharmaceuticals In...

    NASDAQ: AMRX · Real-Time Price · USD
    7.75
    -0.21 (-2.64%)
    At close: Jun 13, 2025, 3:59 PM
    7.75
    -0.06%
    After-hours: Jun 13, 2025, 04:04 PM EDT

    Amneal Pharmaceuticals Statistics

    Share Statistics

    Amneal Pharmaceuticals has 465.54M shares outstanding. The number of shares has increased by 50.82% in one year.

    Shares Outstanding

    n/a
    		 465.54M

    Shares Change (YoY)

    n/a
    		 50.82%

    Shares Change (QoQ)

    n/a
    		 0.77%

    Owned by Institutions (%)

    n/a
    		 40.67%

    Shares Floating

    n/a
    		 167.03M

    Failed to Deliver (FTD) Shares

    n/a
    		 10,719

    FTD / Avg. Volume

    n/a
    		 0.56%

    Short Selling Information

    The latest short interest is 4.2M, so 1.34% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.2M

    Short % of Shares Out

    n/a
    		 1.34%

    Short % of Float

    n/a
    		 2.09%

    Short Ratio (days to cover)

    n/a
    		 3.01

    Valuation Ratios

    The PE ratio is -20.94 and the forward PE ratio is 9.58. Amneal Pharmaceuticals's PEG ratio is 1.

    PE Ratio

    n/a
    		 -20.94

    Forward PE

    n/a
    		 9.58

    PS Ratio

    n/a
    		 0.88

    Forward PS

    n/a
    		 1

    PB Ratio

    n/a
    		 -22.4

    P/FCF Ratio

    n/a
    		 10.06

    PEG Ratio

    n/a
    		 1
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Amneal Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.41, with a Debt / Equity ratio of -23.73.

    Current Ratio

    n/a
    		 1.41

    Quick Ratio

    n/a
    		 0.86

    Debt / Equity

    n/a
    		 -23.73

    Debt / EBITDA

    n/a
    		 5.9

    Debt / FCF

    n/a
    		 10.66

    Interest Coverage

    n/a
    		 0.96

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $336,621.33

    Profits Per Employee

    n/a
    		 $-14,082.65

    Employee Count

    n/a
    		 8,300

    Asset Turnover

    n/a
    		 0.8

    Inventory Turnover

    n/a
    		 2.9

    Taxes

    Income Tax

    n/a
    		 18.86M

    Effective Tax Rate

    n/a
    		 -34.29%

    Stock Price Statistics

    The stock price has increased by 12.48% in the last 52 weeks. The beta is 1.05, so Amneal Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.05

    52-Week Price Change

    n/a
    		 12.48%

    50-Day Moving Average

    n/a
    		 7.42

    200-Day Moving Average

    n/a
    		 8.15

    Relative Strength Index (RSI)

    n/a
    		 56.21

    Average Volume (20 Days)

    n/a
    		 1,919,876

    Income Statement

    In the last 12 months, Amneal Pharmaceuticals had revenue of 2.79B and earned -116.89M in profits. Earnings per share was -0.38.

    Revenue

    n/a
    		 2.79B

    Gross Profit

    n/a
    		 1.02B

    Operating Income

    n/a
    		 249.33M

    Net Income

    n/a
    		 -116.89M

    EBITDA

    n/a
    		 439.77M

    EBIT

    n/a
    		 203.58M

    Earnings Per Share (EPS)

    n/a
    		 -0.38
    Full Income Statement

    Balance Sheet

    The company has 110.55M in cash and 2.59B in debt, giving a net cash position of -2.48B.

    Cash & Cash Equivalents

    n/a
    		 110.55M

    Total Debt

    n/a
    		 2.59B

    Net Cash

    n/a
    		 -2.48B

    Retained Earnings

    n/a
    		 -607.06M

    Total Assets

    n/a
    		 3.37B

    Working Capital

    n/a
    		 434.63M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 295.1M and capital expenditures -51.92M, giving a free cash flow of 243.18M.

    Operating Cash Flow

    n/a
    		 295.1M

    Capital Expenditures

    n/a
    		 -51.92M

    Free Cash Flow

    n/a
    		 243.18M

    FCF Per Share

    n/a
    		 0.79
    Full Cash Flow Statement

    Margins

    Gross margin is 36.52%, with operating and profit margins of 8.92% and -4.18%.

    Gross Margin

    n/a
    		 36.52%

    Operating Margin

    n/a
    		 8.92%

    Pretax Margin

    n/a
    		 -1.97%

    Profit Margin

    n/a
    		 -4.18%

    EBITDA Margin

    n/a
    		 15.74%

    EBIT Margin

    n/a
    		 8.92%

    FCF Margin

    n/a
    		 8.7%

    Dividends & Yields

    AMRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AMRX is $11.5, which is 48.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11.5

    Price Target Difference

    n/a
    		 48.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.66

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist